EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieVergleichsstudieÄquivalenzstudieOpen Access

Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer

W Robert Lee iD, James J Dignam, Mahul B Amin, Deborah W Bruner iD, Daniel Low, Gregory P Swanson iD, Amit B Shah, David D'Souza, Jeff M Michalski iD, Ian S Dayes iD, Samantha A Seaward iD, William A Hall iD und 6 weitere

Journal of Clinical Oncology · 10.07.2024 · 42 (20) · 2377-2381

DOI: 10.1200/jco.23.02445 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.07.2024. Verfasst von W Robert Lee und 17 weiteren Autor:innen. Beteiligte Einrichtung: Duke University Medical Center, Durham, NC. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Dose Fractionation, Radiation. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. NRG Oncology RTOG 0415 is a randomized phase III noninferiority (NI) clinical trial comparing conventional fractionation (73.8 Gy in 41 fractions) radiotherapy (C-RT) with hypofractionation (H-RT; 70 Gy in 28) in patients with low-risk prostate cancer. The study included 1,092 protocol-eligible patients initially reported in 2016 with a median follow-up of 5.8 years. Updated results with median follow-up of 12.8 years are now presented. The estimated 12-year disease-free survival (DFS) is 56.1% (95% CI, 51.5 to 60.5) for C-RT and 61.8% (95% CI, 57.2 to 66.0) for H-RT. The DFS hazard ratio (H-RT/C-RT) is 0.85 (95% CI, 0.71 to 1.03), confirming NI ( P < .001). Twelve-year cumulative incidence of biochemical failure (BF) was 17.0% (95% CI, 13.8 to 20.5) for C-RT and 9.9% (95% CI, 7.5 to 12.6) for H-RT. The HR (H-RT/C-RT) comparing biochemical recurrence between the two arms was 0.55 (95% CI, 0.39 to 0.78). Late grade ≥3 GI adverse event (AE) incidence is 3.2% (C-RT) versus 4.4% (H-RT), with relative risk (RR) for H-RT versus C-RT 1.39 (95% CI, 0.75 to 2.55). Late grade ≥3 genitourinary (GU) AE incidence is 3.4% (C-RT) versus 4.2% (H-RT), RR 1.26 (95% CI, 0.69 to 2.30). Long-term DFS is noninferior with H-RT compared with C-RT. BF is less with H-RT. No significant differences in late grade ≥3 GI/GU AEs were observed between assignments (ClinicalTrials.gov identifier: NCT00331773 ).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsDose Fractionation, RadiationHumansMaleAgedMiddle AgedDisease-Free SurvivalRadiation Dose Hypofractionation

Autor:innen und Institutionen

  • Duke University Medical Center, Durham, NC.
  • Department of Public Health Sciences, University of Chicago, Chicago, IL.
  • NRG Oncology Statistics and Data Management Center, Philadelphia, PA.
  • Cedars-Sinai Medical Center, Los Angeles, CA.
  • Emory University, Atlanta, GA.
  • University of California, Los Angeles, Los Angeles, CA.

ORCID-Profile: W Robert Lee, Deborah W Bruner, Gregory P Swanson, Jeff M Michalski, Ian S Dayes, Samantha A Seaward, William A Hall, Howard M Sandler

Förderung

  • NCI NIH HHS

Zitieren

APA

Lee, W. R., Dignam, J. J., Amin, M. B., Bruner, D. W., Low, D., Swanson, G. P., Shah, A. B., D'Souza, D., Michalski, J. M., Dayes, I. S., Seaward, S. A., Hall, W. A., Nguyen, P. L., Pisansky, T. M., Faria, S. L., Chen, Y., Rodgers, J. P., & Sandler, H. M. (2024). Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer. Journal of Clinical Oncology, 42(20), 2377-2381. https://doi.org/10.1200/jco.23.02445

Vancouver

Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, et al. Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer. Journal of Clinical Oncology. 2024;42(20):2377-2381. doi:10.1200/jco.23.02445

BibTeX
@article{Lee2024,
  author = {Lee, W Robert and Dignam, James J and Amin, Mahul B and Bruner, Deborah W and Low, Daniel and Swanson, Gregory P and Shah, Amit B and D'Souza, David and Michalski, Jeff M and Dayes, Ian S and Seaward, Samantha A and Hall, William A and Nguyen, Paul L and Pisansky, Thomas M and Faria, Sergio L and Chen, Yuhchyau and Rodgers, Joseph P and Sandler, Howard M},
  title = {Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {20},
  pages = {2377--2381},
  doi = {10.1200/jco.23.02445}
}
Kostenlos starten →